Discover the hurdles and breakthroughs in glycoengineering, including the high costs of activated sugars.Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, unveils eversyn's multi-step biocatalysis process, designed to significantly drive down costs and make in vitro glycoengineering more accessible on a large scale.Key Insights:Uncover the power of multistep biocatalysis in driving down costs and making in vitro glycoengineering more accessible.Bridge the Gap between academia and industry in glycoengineering and thus ensure a smoother integration of groundbreaking glycoengineering technologies into the industrial landscape.Gain valuable insights into the challenges and triumphs of transitioning from pure science to entrepreneurship, offering aspiring scientists a roadmap to navigate the unknown.Connect with Thomas Rexer:LinkedIn: https://www.linkedin.com/in/thomas-rexerWebsite: www.eversyn.de